Evidence map›Paper›PMID 29966725›Full record

ReviewInternational journal of radiation oncology, biology, physics2018

The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Robert H Press, Hui-Kuo G Shu, Hyunsuk Shim, James M Mountz, Brenda F Kurland, Richard L Wahl, Ella F Jones, Nola M Hylton, Elizabeth R Gerstner, Robert J Nordstrom and 16 more

Abstract readReview
In one paragraph

Review in International journal of radiation oncology, biology, physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Robert H PressDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Emory University, Atlanta, Georgia. Electronic address: rhpress@emory.edu.
Hui-Kuo G ShuDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Emory University, Atlanta, Georgia.
Hyunsuk ShimDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Emory University, Atlanta, Georgia.
James M MountzDepartment of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Brenda F KurlandDepartment of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
Richard L WahlDepartment of Radiology, Washington University, St. Louis, Missouri.
Ella F JonesDepartment of Radiology, University of California San Francisco, San Francisco, California.
Nola M HyltonDepartment of Radiology, University of California San Francisco, San Francisco, California.
Elizabeth R GerstnerDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Robert J NordstromCancer Imaging Program, National Cancer Institute, Bethesda, Maryland.
Lori HendersonCancer Imaging Program, National Cancer Institute, Bethesda, Maryland.
Karen A KurdzielMolecular Imaging Program, National Cancer Institute, Bethesda, Maryland.
Bhadrasain VikramRadiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.
Michael A JacobsDepartment of Radiology and Radiological Science, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Matthias HoldhoffBrain Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
Edward TaylorPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
David A JaffrayPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Lawrence H SchwartzDepartment of Radiology, Columbia University Medical Center, Columbia University, New York, New York.
David A MankoffDepartment of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania.
Paul E KinahanDepartment of Radiology, University of Washington, Seattle, Washington.
Hannah M LindenDepartment of Medicine, University of Washington, Seattle, Washington.
Philippe LambinDepartment of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Thomas J DillingDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Daniel L RubinDepartment of Radiology, Stanford University, Stanford, California.
Lubomir HadjiiskiDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.
John M BuattiDepartment of Radiation Oncology, University of Iowa, Iowa City, Iowa.

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer OutcomesP01CA210961 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Laura J Van't Veer · 2017 to 2026
$22.9M
Elimination of Instrumental Bias for Quantitative Diffusion Imaging in Clinical Oncology TrialsR01CA190299 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MALYARENKO, DARIYA I. · 2015 to 2025
$6.4M
Multi-Modality Quantitiative Imaging for Evaluation of Response to Cancer TherapyU01CA140204 · NCI · JOHNS HOPKINS UNIVERSITY · PI DU, YONG, SOLNES, LILJA · 2011 to 2022
$6.1M
Advanced PET/CT Imaging for Improving Clinical TrialsU01CA148131 · NCI · UNIVERSITY OF WASHINGTON · PI KINAHAN, PAUL E., LINDEN, HANNAH M · 2010 to 2019
$6.0M
Quantitative Imaging to Assess Response in Cancer Therapy TrialsU01CA140206 · NCI · UNIVERSITY OF IOWA · PI BUATTI, JOHN M, CASAVANT, THOMAS L. · 2010 to 2019
$5.8M
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment TrialsR01CA132870 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HYLTON-WATSON, NOLA M., NEWITT, DAVID C · 2008 to 2019
$4.8M
Quantitative imaging tools to derive DW-MRI oncological biomarkersU01CA211205 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVE, AMITA, SCHWARTZ, LAWRENCE H · 2017 to 2021
$3.4M
Quantitative MRSI to predict early response to SAHA therapy in new GBM managementU01CA172027 · NCI · EMORY UNIVERSITY · PI BARKER, PETER B, HU, XIAOPING P · 2013 to 2017
$3.2M
ECOG-ACRIN-Based QIN Resource for Advancing Quantitative Cancer Imaging in Clinical TrialsU01CA190254 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI SCHNALL, MITCHELL D. · 2015 to 2019
$3.2M
NCI NIH HHS K23 CA169021NCI NIH HHS P01 CA210961NCI NIH HHS P30 CA016520NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA132870NCI NIH HHS R01 CA190299NCI NIH HHS R01 CA194783NCI NIH HHS R01 CA211238NCI NIH HHS R01 CA211337NCI NIH HHS R01 CA214557NCI NIH HHS R33 CA225310NCI NIH HHS U01 CA140204NCI NIH HHS U01 CA140206NCI NIH HHS U01 CA140230NCI NIH HHS U01 CA148131NCI NIH HHS U01 CA172027NCI NIH HHS U01 CA179106NCI NIH HHS U01 CA187947NCI NIH HHS U01 CA190214NCI NIH HHS U01 CA190254NCI NIH HHS U01 CA211205
6 · The paper itself

Abstract

Modern radiation therapy is delivered with great precision, in part by relying on high-resolution multidimensional anatomic imaging to define targets in space and time. The development of quantitative imaging (QI) modalities capable of monitoring biologic parameters could provide deeper insight into tumor biology and facilitate more personalized clinical decision-making. The Quantitative Imaging Network (QIN) was established by the National Cancer Institute to advance and validate these QI modalities in the context of oncology clinical trials. In particular, the QIN has significant interest in the application of QI to widen the therapeutic window of radiation therapy. QI modalities have great promise in radiation oncology and will help address significant clinical needs, including finer prognostication, more specific target delineation, reduction of normal tissue toxicity, identification of radioresistant disease, and clearer interpretation of treatment response. Patient-specific QI is being incorporated into radiation treatment design in ways such as dose escalation and adaptive replanning, with the intent of improving outcomes while lessening treatment morbidities. This review discusses the current vision of the QIN, current areas of investigation, and how the QIN hopes to enhance the integration of QI into the practice of radiation oncology.

Indexed as

HumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyNeoplasmsPositron-Emission TomographyRadiation OncologyTomography, X-Ray ComputedTumor Hypoxia

Identifiers

PMID29966725
PMCPMC6348006

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.